TLDRs;
-
The court dismissed the J&J talc fraud suit and the stock dipped slightly to $227.29.
-
Investors are watching potential talc lawsuit appeals and how they might impact share prices.
-
Medicare drug pricing negotiations could influence J&J profits despite a strong 2026 outlook.
-
Income investors should note the February 24 ex-dividend date with the payout set for March 10.
Johnson & Johnson (NYSE: JNJ) saw its stock edge lower on Thursday, closing at $227.29, down 0.19%, after a U.S. federal judge dismissed a high-profile lawsuit accusing the company of fraud in managing its talc liabilities. During after-hours trading, shares recovered slightly, reaching $227.98.
The case centered on J&J’s so-called “Texas two-step” strategy, where talc-related claims are shifted into a subsidiary that then declares bankruptcy. U.S. District Judge Michael Shipp ruled that the plaintiffs had not demonstrated harm from bankruptcy stays that delayed litigation between October 2021 and March 2025. J&J’s head of litigation, Erik Haas, described the claims as “wholly meritless.”
Talc Litigation Remains a Key Risk
Despite the dismissal, talc-related lawsuits continue to pose a significant legal challenge for the pharmaceutical giant. In December, a Baltimore jury awarded $1.5 billion to a plaintiff who linked her cancer to asbestos in J&J talc products. The company has announced plans to appeal and is currently facing over 67,000 related cases nationwide.
U.S. District Judge Michael Shipp dismissed a lawsuit alleging Johnson & Johnson committed fraud by attempting to resolve lawsuits claiming its talc products caused cancer through a shell company's bankruptcy.
More Here → https://t.co/HMGjD0Gqtd
— PiQ (@PiQSuite) January 29, 2026
Investors closely monitor each court ruling, as any significant judgment could impact the company’s stock and broader pharmaceutical sector sentiment. Analysts note that the market has largely priced in these risks, but unexpected developments could trigger volatility.
Strong 2026 Outlook Faces External Pressures
Outside the courtroom, J&J projects robust growth for 2026. The company expects sales between $99.5 billion and $100.5 billion, with earnings per share ranging from $11.43 to $11.63, both exceeding Wall Street expectations. CEO Joaquin Duato emphasized that revenue growth in 2026 is set to surpass 2025, despite roughly $500 million in anticipated tariffs affecting its medical devices division.
However, drug pricing pressures remain a concern. Under the Inflation Reduction Act, Medicare will begin price negotiations for 15 selected drugs in 2028.
While analysts, including BMO’s Evan Seigerman, consider the impact manageable, CFO Joseph Wolk warned that pricing agreements could shave hundreds of millions from projected profits. Additionally, increasing competition from biosimilars, particularly against J&J’s psoriasis treatment Stelara, adds another layer of uncertainty.
Market Eyes Dividend and Upcoming Sessions
Investors are also preparing for the ex-dividend date on February 24. J&J’s board announced a $1.30 quarterly payout, scheduled for March 10. Traders purchasing shares after the ex-dividend date will not receive this upcoming distribution.
The short-term outlook for JNJ hinges on whether plaintiffs appeal Thursday’s dismissal and the pace of talc lawsuits in New Jersey. With the stock near recent highs, Friday’s trading session could reveal whether market confidence in J&J as a stable healthcare investment remains intact or if legal concerns weigh on investor sentiment.
As markets digest the latest court decision and look ahead to potential appeals and regulatory developments, J&J’s performance will likely remain a focal point for healthcare investors and traders seeking exposure to pharmaceutical giants navigating complex legal landscapes.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
